Drug Profile


Alternative Names: BY 2001; Lung surfactant factor; Recombinant surfactant protein C; rSP-C; Venticute

Latest Information Update: 02 Apr 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Scios
  • Developer Nycomed
  • Class Phospholipids; Pulmonary surfactants; Recombinant proteins; Surfactants
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adult respiratory distress syndrome

Highest Development Phases

  • Discontinued Adult respiratory distress syndrome

Most Recent Events

  • 01 Jun 2007 Lusupultide received Fast Track designation for Adult respiratory distress syndrome [Intratracheal] in the US
  • 02 Sep 2004 A study has been added to the Respiratory Tract Disorders therapeutic trials section
  • 16 Jun 2004 Phase-III clinical trials in Adult respiratory distress syndrome in European Union (Intratracheal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top